First‐generation tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, significantly improve progression‐free survival in stage IV lung cancer patients who are positive for activating EGFR mutations such as L858R and del19 4. Here, EGFR is linked to lung carcinoma.